Short-Term Debt to Equity Ratio: Trevena, Inc. (TRVN)

Graphic logo of Trevena Inc (TRVN)

Trevena, Inc. (TRVN) is implementing IT solutions for digital drug modeling to minimize manual laboratory labor. The company's price evolution confirms the current 0.00 metric. However, global conflicts and sanctions are blocking logistics and international trials. The situation is exacerbated by the sales failure of its primary analgesic, which has triggered a funding shortage, delisting, and the threat of a complete cessation of all business processes.

Ratio of Short-Term Indebtedness to Capital: Trevena, Inc (TRVN) for 07/04/2022 - 10/19/2024
Product sample of Trevena

To find a balance between asset quality and business valuation, investors analyze the ratio of short-term liabilities to equity, which allows for an assessment of the risk of excessive debt load during expansion. In the case of Trevena, Inc. (TRVN), where a liquidity deficit has constrained operational growth and diverted remaining cash to cover administrative expenses, the short-term leverage ratio clearly demonstrates the stability of the company's financial structure.

Competitors of Trevena, Inc. (TRVN)

Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Ratio CPRX|DNLI (denalitherapeutics.com) - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN (Biohaven Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AMLX (Amylyx)|Trevi Corp (TRVI) - Current Liabilities to Capital|PRAX: Short-Term Debt to Equity Ratio|AVXL: Short-Term Debt to Equity|CBLL: Short-Term Debt to Capital|Current Liabilities to Capital Prothena Biosciences (PRTA)|Short-Term Debt to Equity Alector Inc.|Short-Term Debt to Capital Ratio ANNX (Annexon Biosciences Inc.)|Short-Term Debt to Capital OMER|Short-Term Debt to Capital neurogene.com (NGNE)|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|Neumora Therapeutics Inc - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Scilex Holding Company, Inc. SCLX|Tevogen Bio Holdings (TVGN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio ACOG|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Inhibikase Therapeutics Inc (IKT)|Short-Term Debt to Equity Ratio SAVA (Cassava)|Short-Term Debt to Capital Coefficient assertiotx.com|Coya Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio VTGN (VistaGen Therapeutics, Inc.)|OVID - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ABOS (Acumen Pharmaceuticals Inc.)|CRVO (CervoMed Inc) - Short-Term Debt to Equity Ratio|ATHE (Alterity Therapeutics Limited) - Short-Term Debt to Equity|Short-Term Debt to Equity Clene Inc|Short-Term Debt to Capital Ratio PEPG (PepGen Corp)|Short-Term Debt to Equity Jupiter Neurosciences (JUNS)|Relmada Therapeutics Inc - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|Grace Therapeutics Inc (GRCE) - Current Liabilities to Capital|AIFF: Short-Term Debt to Equity Ratio|KLTO - Short-Term Debt to Capital|neurosense-tx.com (NRSN) - Short-Term Debt to Equity|Reviva Pharmaceuticals Holdings Inc. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity MetaVia Inc.|Current Liabilities to Capital NeurAxis Inc NRXS|Short-Term Debt to Equity Ratio HSDT (Helius Medical)|Short-Term Loans to Capital Ratio PASG|Short-Term Debt to Equity Neuphoria Therapeutics NEUP|Ratio of Short-Term Indebtedness to Capital NERV|Athira - Short-Term Debt to Capital|Current Liabilities to Capital Addex|ALZN (alzamend.com) - Short-Term Debt to Equity Ratio|CYCN (Cyclerion Therapeutics, Inc.) - Short-Term Debt to Equity|PTIX (Protagenic Therapeutics Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Pasithea KTTA|Short-Term Debt to Equity Cortigent, Inc. (CRGT)|Avenue Therapeutics Inc - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital BCLI (Brainstorm Cell)|Short-Term Debt to Capital caratherapeutics.com CARA|CHRO: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ELYM (Eliem Therapeutics)|ITCI: Short-Term Debt to Capital|LBPH - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Marinus Pharmaceuticals|Short-Term Debt to Capital Ratio NKGN (nkgenbiotech.com)|Short-Term Debt to Capital NRBO|Short-Term Debt to Equity Ratio Sage Therapeutics Inc. SAGE|Neurotrope - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient Vigil Neuroscience Inc. (VIGL)|WENA: Short-Term Debt to Equity Ratio|cerevel.com - Short-Term Loans to Capital Ratio